Page 37 - Livre électronique du Congrès National de Pneumologie 2019
P. 37

THE PREVALENCE OF SEVERE UNCONTROLLED ASTHMA IN A
                               TUNISIAN POPULATION.


                 C3











               Introduction

               The goals of asthma treatment are to achieve good symptom control and minimal exacerbations.
               Some patients, despite being on maximal therapy with managed comorbidities remain uncontrolled.
               They constitute cases of severe uncontrolled asthma and they may be eligible for biologic therapies.

               Aim: to determine the prevalence of severe uncontrolled asthma in Tunisia.

               Methods

               This  was  a  cross  sectional  study  conducted  in  the  department  of  physiology  and  Functional
               explorations. 102 adult patients with asthma were enrolled. A medical questionnaire was used to
               assess for comorbidities, medication (classified from step 1 to 5 according to GINA 2018), adherence
               to treatment and symptom control level (according to GINA 2018).

               Results

               The sample was aged 44.3±13.3 years with 70% of females. The main comorbidities reported were
               rhinitis (83.3%), conjunctivitis (42.2%), GERD (34.3%) and obesity (48%). Uncontrolled asthma was
               found in 59.8% of the patients (n=61). They were so because they were untreated (9.8%) or difficult
               to  treat  (45.1%) because  of  poor  adherence to treatment  (n=35)  and unmanaged  comorbidities
               (n=11). Only five patients of the total sample (4.9%, IC95%[1-9.8]) were “authentic” uncontrolled
               severe asthma.

               Conclusion

               Most of uncontrolled patients are difficult to treat ones. The prevalence of severe uncontrolled asthma
               in Tunisia is only 4.9%, IC95% [1-9.8]. With a prevalence of less than 5%, uncontrolled severe asthma
               is a rare phenotype and the reimbursement of novel targeted treatment should be facilitated in these
               patients.
   32   33   34   35   36   37   38   39   40   41   42